Ian Flinn, MD
Enriched profileChief Scientific Officer, OneOncology and Tennessee Oncology's Greco-Hainsworth Tennessee Oncology Centers for Research (appointed November 2023) · Tennessee Oncology
Ian Flinn is Chief Scientific Officer, OneOncology and Tennessee Oncology's Greco-Hainsworth Tennessee Oncology Centers for Research (appointed November 2023) at Tennessee Oncology. OpenAlex indexes 933 publications with 55,739 citations (h-index 96); ClinicalTrials.gov lists 19 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Hematology / Oncology profiles in the findmyKOL directory.
Data verified 14 Aug 2026
Overview
Updated 14 Oct 2026
Ian Flinn, M.D., is Chief Scientific Officer, OneOncology and Tennessee Oncology's Greco-Hainsworth Tennessee Oncology Centers for Research (appointed November 2023). The public record shows 933 publications with 55,739 citations (h-index 96), centered on Chronic Lymphocytic Leukemia Research, Lymphoma Diagnosis and Treatment, CAR-T cell therapy research. It also documents an investigator role on 19 registered clinical trials, industry payments reported by 39 companies.
- Most recent indexed publication: 2026 · Blood
- Top research focus: Chronic Lymphocytic Leukemia Research
- 19 registered trials on ClinicalTrials.gov
- Open Payments reporting from 39 companies
Generated from the cited public record · current as of 14 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 41 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 414.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 14 Oct 2026
Listed as an investigator on 19 registered studies on ClinicalTrials.gov. The most recent:
- CAR-T Long Term Follow Up (LTFU) Study
Sponsor: Novartis Pharmaceuticals
Industry payments
Updated 14 Oct 2026
39 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Gilead Sciences, Inc.Program year20251 payment
- BeOne Medicines USA, Inc.Program year20254 payments
- ABBVIE INC.Program year20256 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
71.5%Human Immunoglobulin G69.7%Immune globulin100%Part B, office-administered≥14 patientsShort-acting sulfonamides1.1%Sulfamethoxazole-Trimethoprim100%Part D<11 patients+ 2 more classes in this area
Sensory organs
12.5%Corticosteroid12.5%Dexamethasone sodium phosphate95%Dexamethasone5%Part D + Part B<11 patientsCancer & immunology
11.6%Kinase inhibitor8.5%Calquence36%Brukinsa31%Imbruvica15%Jaypirca8%Tasigna4%Jakafi3%Sprycel3%Part D<11 patientsBCL-2 Inhibitor2.2%Venclexta100%Part D≥15 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Congress activity
Updated 14 Oct 2026
242 congress contributions (2004–2026) across AACR, ASCO, ASH, ASTRO per OpenAlex. The most recent:
- Combination of zanubrutinib (zanu) + venetoclax (ven) for treatment-naive (TN) CLL/SLL: Results in SEQUOIA arm D.
ASCO Annual Meeting
ASCO2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 14 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Addition of Ianalumab (VAY736) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia on Ibrutinib Therapy: Results from a Phase Ib Study.
Clinical cancer research
Clinical Trial2025 - Zanubrutinib is well tolerated and effective in patients with CLL/SLL intolerant of ibrutinib/acalabrutinib: updated results.
Blood advances
Clinical Trial2025
Most-cited works
by citation count (OpenAlex)- 01Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell LymphomaArticle5,985 citations2017
- 02
- 03Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic LeukemiaArticle2,264 citations2013
- 04KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell LymphomaArticle1,843 citations2020
- 05Idelalisib and Rituximab in Relapsed Chronic Lymphocytic LeukemiaArticle1,691 citations2014
Network
Updated 14 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 14 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- ResearchGate
researchgate.net/scientific-contributions/Ian-W-Flinn-2145166940
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
Mentions by others
where others cite or feature them- Facebook
facebook.com/tennesseeoncology/posts/tennessee-oncologys-dr-ian-flinn-director-of-lymphoma-research-at-sarah-canon-re/2098524106946326
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →facebook.com ↗ - Other
vjhemonc.com/speaker/ian-flinn
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →vjhemonc.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 14 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- M.D.
Johns Hopkins University School of Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →tnoncology.com ↗ - Ph.D. in Clinical Investigation
Johns Hopkins University School of Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →tnoncology.com ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →healthgrades.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →healthgrades.com ↗
Editorial & leadership roles
journal and society appointments- Member
American Society of Hematology (ASH)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →tnoncology.com ↗ - Member
American Society of Clinical Oncology (ASCO)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →tnoncology.com ↗ - Member
CLL Research Consortium
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →ajmc.com ↗ - Editorial Board
touchONCOLOGY
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →touchoncology.com ↗
Secondary affiliations
appointments beyond the home institution- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oneoncology.com ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vjhemonc.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →patientpower.info ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Bipin Savani, MD
Tennessee Oncology
Lester Porter, MD
Tennessee Oncology
Annis Marney, MD, MSCI
Tennessee Oncology
Shakthi Bhaskar, MD
Tennessee Oncology
Hagop Kantarjian, MD
The University of Texas MD Anderson Cancer Center
Jorge Cortes, MD
University of Alabama at Birmingham (UAB)
Ayalew Tefferi, MD
Mayo Clinic
Charles Sawyers, MD
Memorial Sloan Kettering Cancer Center